Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will announce its interim results for the six months ended 31 December 2024 on Tuesday, 11 March 2025.
Aptamer Group to publish interim results on Tuesday 11th March
- Written by: Amilia Stone
Find more news, interviews, share price & company profile here for:
Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes.
Aptamer Group posted unaudited revenue of £1.20 million for the year ended 30 June 2025, up 41% from the previous year. The company secured two new royalty agreements and advanced multiple licensing discussions, supported by a strengthened cash position following a £1.83 million fundraise.
Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials.
Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery.
Aptamer Group plc has raised £2.0 million (before expenses) via a placing of new ordinary shares at 0.3p per share, representing a 21.1% discount.
Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells.
